Despite recent advances in the production of antiviral therapeutics, there is no effective prophylactic vaccine for HCV infection due to the high rate of genetic variation of the HCV virus genome during replication in human host cells. HCV isolates are divided into six main genotypes (from 1 to ...
Respiratory viruses are a major cause of death worldwide, with an estimated 2.7 million attributable deaths in 20151. While a vaccine to prevent RSV infection may be on the horizon2,3, protective vaccines for HMPV, HPIV3, and HPIV1 are not yet clinically available. Even if protective vacci...
Phase III HEV 239 trial presented evidence for the protection against HEV GT1, as could be anticipated since HEV 239 corresponds to ORF2 of HEV GT1 [78]. In lines with expectations, monoclonal competition assay found that patients who had received the HEV 239 vaccine developed broadly cross-...
Respiratory viruses are a major cause of death worldwide, with an estimated 2.7 million attributable deaths in 20151. While a vaccine to prevent RSV infection may be on the horizon2,3, protective vaccines for HMPV, HPIV3, and HPIV1 are not yet clinically available. Even if protective vacci...